S&P 500

5.431,60

-0,04%

Negocie como um profissional: Aproveite discussões em tempo real e ideias que movimentam o mercado para superar a concorrência.

Cadastre-se

Início
Investir
Ações
EUA
NASDAQ
Editas Medicine Inc (EDIT)
Editas Medicine Inc (EDIT) Notícias

EDIT

Editas Medicine (EDIT)

Editas Medicine Inc

De:

Notícias regulamentadas

Procure um Texto:

Ordenação:

Notícias não regulamentadas

Apresentando as notícias mais relevantes sobre:NASDAQ:EDIT

1 2 3 4 5 6 7 8 9 Próxima >>

Data	Hora	Fonte	Título	Código	Companhia
14/06/2024	07:04	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:EDIT	Editas Medicine Inc
14/06/2024	04:01	GlobeNewswire Inc.	Editas Medicine Reports New Safety and Efficacy Data from the RUBY Trial of Reni-cel in 18 Patients with Sickle Cell Disease, Presented at the European Hematology Association (EHA) Annual Congress	NASDAQ:EDIT	Editas Medicine Inc
14/06/2024	04:00	GlobeNewswire Inc.	Editas Medicine Announces New Safety and Efficacy Data from the EdiTHAL Trial of Reni-cel in 7 Patients with Transfusion-dependent Beta Thalassemia, Presented at the European Hematology Association (EHA) Annual Congress	NASDAQ:EDIT	Editas Medicine Inc
06/06/2024	17:17	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:EDIT	Editas Medicine Inc
31/05/2024	17:21	Edgar (US Regulatory)	Form 144 - Report of proposed sale of securities	NASDAQ:EDIT	Editas Medicine Inc
10/05/2024	07:00	GlobeNewswire Inc.	Editas Medicine Preclinical Data Highlights Advancement of in vivo Gene Editing Medicine Technologies at the American Society of Gene and Cell Therapy Annual Meeting	NASDAQ:EDIT	Editas Medicine Inc
08/05/2024	17:21	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:EDIT	Editas Medicine Inc
08/05/2024	09:29	IH Market News	U.S. Futures Slightly Dip Amid Corporate Earnings and Quiet Economic Calendar, Oil Prices Fall	NASDAQ:EDIT	Editas Medicine Inc
08/05/2024	08:00	GlobeNewswire Inc.	Editas Medicine Announces First Quarter 2024 Results and Business Updates	NASDAQ:EDIT	Editas Medicine Inc
02/05/2024	08:00	GlobeNewswire Inc.	Editas Medicine Announces First Quarter 2024 Results Conference Call and Upcoming Investor Events	NASDAQ:EDIT	Editas Medicine Inc
01/05/2024	09:00	GlobeNewswire Inc.	Editas Medicine and Bristol Myers Squibb Extend Alpha-Beta T Cell Collaboration	NASDAQ:EDIT	Editas Medicine Inc
22/04/2024	17:31	GlobeNewswire Inc.	Editas Medicine to Present Pre-clinical Data Demonstrating Progression of in vivo Medicines Pipeline at the American Society of Gene and Cell Therapy Annual Meeting	NASDAQ:EDIT	Editas Medicine Inc
28/02/2024	19:13	Edgar (US Regulatory)	Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuers	NASDAQ:EDIT	Editas Medicine Inc
28/02/2024	18:39	Edgar (US Regulatory)	Form S-8 - Securities to be offered to employees in employee benefit plans	NASDAQ:EDIT	Editas Medicine Inc
28/02/2024	09:00	GlobeNewswire Inc.	Editas Medicine Announces Fourth Quarter and Full Year 2023 Results and Business Updates	NASDAQ:EDIT	Editas Medicine Inc
21/02/2024	09:00	GlobeNewswire Inc.	Editas Medicine Announces Fourth Quarter and Full Year 2023 Results Conference Call and Upcoming Investor Events	NASDAQ:EDIT	Editas Medicine Inc
14/02/2024	10:40	Edgar (US Regulatory)	Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]	NASDAQ:EDIT	Editas Medicine Inc
31/01/2024	11:00	GlobeNewswire Inc.	Editas Medicine to Participate in Upcoming Investor Conferences	NASDAQ:EDIT	Editas Medicine Inc
08/01/2024	10:15	GlobeNewswire Inc.	Editas Medicine Highlights 2024 Anticipated Milestones and Strategic Priorities at the J.P. Morgan Healthcare Conference	NASDAQ:EDIT	Editas Medicine Inc
03/01/2024	09:00	GlobeNewswire Inc.	Editas Medicine to Present at the 42nd Annual J.P. Morgan Healthcare Conference	NASDAQ:EDIT	Editas Medicine Inc
13/12/2023	14:48	Dow Jones News	Editas Medicine Strikes License Deal With Vertex Pharmaceuticals -- Update	NASDAQ:EDIT	Editas Medicine Inc
13/12/2023	11:49	Dow Jones News	Editas Medicine Strikes License Deal With Vertex Pharmaceuticals	NASDAQ:EDIT	Editas Medicine Inc
13/12/2023	11:00	GlobeNewswire Inc.	Editas Medicine and Vertex Pharmaceuticals Enter into Non-exclusive License Agreement for Cas9	NASDAQ:EDIT	Editas Medicine Inc
11/12/2023	14:00	GlobeNewswire Inc.	Editas Medicine Announces New EDIT-301 Safety and Efficacy Data in 17 Patients, Presented Today at the American Society of Hematology (ASH) Annual Meeting and in a Company-sponsored Webinar	NASDAQ:EDIT	Editas Medicine Inc
03/11/2023	08:00	GlobeNewswire Inc.	Editas Medicine Announces Third Quarter 2023 Results and Business Updates	NASDAQ:EDIT	Editas Medicine Inc
02/11/2023	10:12	GlobeNewswire Inc.	Editas Medicine to Present Clinical Data from the RUBY and EdiTHAL Trials of EDIT-301 at the ASH 2023 Annual Meeting and in a Company-sponsored Webinar	NASDAQ:EDIT	Editas Medicine Inc
27/10/2023	08:00	GlobeNewswire Inc.	Editas Medicine Announces Third Quarter 2023 Results Conference Call and Upcoming Investor Events	NASDAQ:EDIT	Editas Medicine Inc
16/10/2023	09:00	GlobeNewswire Inc.	Editas Medicine Granted FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for EDIT-301 for the Treatment of Severe Sickle Cell Disease	NASDAQ:EDIT	Editas Medicine Inc
25/09/2023	17:30	GlobeNewswire Inc.	Editas Medicine Reports Inducement Grants to New Chief Commercial and Strategy Officer	NASDAQ:EDIT	Editas Medicine Inc
25/09/2023	10:00	GlobeNewswire Inc.	Editas Medicine Strengthens Executive Leadership Team with Appointment of Caren Deardorf as Chief Commercial and Strategy Officer	NASDAQ:EDIT	Editas Medicine Inc